Daniel Wang et al. published a recruitment notice for a phase I clinical trial of HNSCC treatment on the website in 2018 to explore the safety and cytotoxicity of HER2-targeting CAR-T cells combined with an intra-tumor injection of binary oncolytic adenovirus CAdVEC against HER2-positive tumors, including HNSCC. Here, ERBB2 is linked to neoplasm.